Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • anti-PD1

    - PMLiVE

    BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation

    The report shows how prehabilitation can improve patient experience while alleviating capacity pressures

    - PMLiVE

    BMS acquires Orbital Therapeutics in $1.5bn deal

    The deal includes several next-gen cell therapy candidates for autoimmune diseases

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    EMA reaffirms guidance on paracetamol use during pregnancy

    The guidance follows recent US comments about a possible link to autism

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

    This follows preliminary results from the company's ongoing phase 2 trial

    - PMLiVE

    Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

    Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

    - PMLiVE

    Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

    The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    - PMLiVE

    NHS programme to give melanoma patients fast-track access to skin cancer vaccine

    The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

    - PMLiVE

    BMS receives FDA approval for immunotherapy combination in liver cancer

    Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

    - PMLiVE

    BMS granted FDA approval for immunotherapy combination in colorectal cancer

    More than 154,000 cases of the disease are expected to be diagnosed in the US this year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links